Cargando…

Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial

OBJECTIVE: There are no direct comparisons between escitalopram and paroxetine controlled release in patients with major depressive disorder (MDD). METHODS: We conducted a 24-week, rater-masked, randomized trial of escitalopram (5–20 mg/day) versus paroxetine controlled release (12.5–50 mg/day) in p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kishi, Taro, Matsuda, Yuki, Matsunaga, Shinji, Moriwaki, Masatsugu, Otake, Yoichiro, Akamatsu, Kaku, Okochi, Tomo, Hirano, Shigeki, Funahashi, Toshihiko, Okuda, Momoko, Tabuse, Hideaki, Fujita, Kiyoshi, Iwata, Nakao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5230634/ https://www.ncbi.nlm.nih.gov/pubmed/28123299 http://dx.doi.org/10.2147/NDT.S124898

Ejemplares similares

Comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan: a 4-week open-label, parallel-group study of major depressive disorder
por: Nagao, Kei, et al.
Publicado: (2013)

A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders
por: Kishi, Taro, et al.
Publicado: (2016)

A comparative review of escitalopram, paroxetine, and sertraline: are they all alike?
por: Sanchez, Connie, et al.
Publicado: (2014)

Encapsulated Escitalopram and Paroxetine Intranasal Co-Administration: In Vitro/In Vivo Evaluation
por: Silva, Soraia, et al.
Publicado: (2021)

Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
por: Huang, Jia, et al.
Publicado: (2018)

Effects of escitalopram and paroxetine on mTORC1 signaling in the rat hippocampus under chronic restraint stress
por: Seo, Mi Kyoung, et al.
Publicado: (2017)

Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
por: Kishi, Taro, et al.
Publicado: (2015)

Memantine Monotherapy for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
por: Matsunaga, Shinji, et al.
Publicado: (2015)

Combination Therapy with Cholinesterase Inhibitors and Memantine for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
por: Matsunaga, Shinji, et al.
Publicado: (2015)

Memantine for the treatment of frontotemporal dementia: a meta-analysis
por: Kishi, Taro, et al.
Publicado: (2015)

PT592. Memantine Monotherapy for Alzheimer’s Disease: A Systematic Review and Meta-analysis
por: Matsunaga, Shinji, et al.
Publicado: (2016)

Memantine treatment for Japanese patients with moderate to severe Alzheimer’s disease: a meta-analysis of double-blind, randomized, placebo-controlled trials
por: Kishi, Taro, et al.
Publicado: (2018)

The effects of memantine on behavioral disturbances in patients with Alzheimer’s disease: a meta-analysis
por: Kishi, Taro, et al.
Publicado: (2017)

Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials
por: Kishi, Taro, et al.
Publicado: (2018)

Cholinesterase Inhibitors for Lewy Body Disorders: A Meta-Analysis
por: Matsunaga, Shinji, et al.
Publicado: (2015)

Iminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramine
por: Kishi, Taro, et al.
Publicado: (2014)

Aripiprazole for the management of schizophrenia in the Japanese population: a systematic review and meta-analysis of randomized controlled trials
por: Kishi, Taro, et al.
Publicado: (2015)

Paroxetine versus Venlafaxine and Escitalopram in Korean Patients with Major Depressive Disorder: A Randomized, Rater-blinded, Six-week Study
por: Woo, Young Sup, et al.
Publicado: (2017)

Early prediction of blonanserin response in Japanese patients with schizophrenia
por: Kishi, Taro, et al.
Publicado: (2014)

Protection against Brain Atrophy by Anti-dementia Medication in Mild Cognitive Impairment and Alzheimer’s Disease: Meta-Analysis of Longitudinal Randomized Placebo-Controlled Trials
por: Kishi, Taro, et al.
Publicado: (2015)

Efficacy and tolerability of topiramate-augmentation therapy for schizophrenia: a systematic review and meta-analysis of randomized controlled trials
por: Okuyama, Yuji, et al.
Publicado: (2016)

Paroxetine overdose
por: Gupta, Arun K., et al.
Publicado: (2005)

Anti-Dementia Drugs for Psychopathology and Cognitive Impairment in Schizophrenia: A Systematic Review and Meta-Analysis
por: Kishi, Taro, et al.
Publicado: (2018)

Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population
por: Kishi, Taro, et al.
Publicado: (2017)

Suvorexant for insomnia in patients with psychiatric disorder: A 1‐week, open‐label study
por: Kishi, Taro, et al.
Publicado: (2019)

Antidepressant and Neuroprotective Effects of 3-Hydroxy Paroxetine, an Analog of Paroxetine in Rats
por: Hernández-Arrambide, Pedro Efraín, et al.
Publicado: (2022)

Association Analysis of Nuclear Receptor Rev-erb Alpha Gene (NR1D1) and Japanese Methamphetamine Dependence
por: Kishi, Taro, et al.
Publicado: (2011)

Paroxetine-induced galactorrhea
por: Gulati, Prannay, et al.
Publicado: (2014)

Paroxetine-induced galactorrhea
por: Petrykiv, S., et al.
Publicado: (2022)

Comparison Between Tadalafil Plus Paroxetine and Paroxetine Alone in the Treatment of Premature Ejaculation
por: Moudi, Emadouddin, et al.
Publicado: (2016)

Cardiometabolic Risks of Blonanserin and Perospirone in the Management of Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Kishi, Taro, et al.
Publicado: (2014)

Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials
por: Oya, Kazuto, et al.
Publicado: (2015)

Long-Acting Injectable Antipsychotics for Prevention of Relapse in Bipolar Disorder: A Systematic Review and Meta-Analyses of Randomized Controlled Trials
por: Kishi, Taro, et al.
Publicado: (2016)

Plasma levels of IL-6 in patients with untreated major depressive disorder: comparison with catecholamine metabolites
por: Yoshimura, Reiji, et al.
Publicado: (2019)

Mitochondrial modulators for obsessive–compulsive and related disorders: a systematic review and meta-analysis
por: Kishi, Taro, et al.
Publicado: (2022)

Paliperidone palmitate vs. paliperidone extended-release for the acute treatment of adults with schizophrenia: a systematic review and pairwise and network meta-analysis
por: Kishi, Taro, et al.
Publicado: (2022)

Paroxetine‐induced QTc prolongation
por: Otsuka, Yuji
Publicado: (2017)

Paroxetine overdose during pregnancy
por: Acar, Selin, et al.
Publicado: (2021)

Recent findings on subjective well‐being and physical, psychiatric, and social comorbidities in individuals with schizophrenia: A literature review
por: He, Yupeng, et al.
Publicado: (2022)

Physical, Psychiatric, and Social Comorbidities of Individuals with Schizophrenia Living in the Community in Japan
por: Matsunaga, Masaaki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t6cjj7obph2hvn2msl23e1d6o2